Prolonging sEV Circulation for Drug Delivery: Integrating Cellular Origin With Surface Bioengineering
WIREs Nanomedicine and Nanobiotechnology · 2026-11 · 18 (6)
DOI: 10.1002/wnan.70093 ↗Kurz gefasst
Fachartikel in der Zeitschrift WIREs Nanomedicine and Nanobiotechnology, online erschienen am 21.11.2026. Verfasst von Wen‐Hao Jia und 5 weiteren Autor:innen. Die Arbeit nennt 152 Literaturangaben.
Abstract (Originalsprache)
Small extracellular vesicle (sEV)‐based therapies are emerging as multifunctional drug delivery platforms. These membrane‐enclosed vesicles are generally reported to have diameters below 200 nm, depending on the isolation and characterization methods used. However, their rapid clearance from the bloodstream remains a major obstacle to clinical translation. This review summarizes the mechanisms underlying the pharmacokinetics of sEVs and proposes a design framework for extending the circulation half‐life of sEVs by integrating cellular sources with surface bioengineering approaches. We first outline key clearance pathways, including sequestration by the mononuclear phagocyte system, opsonization and protein corona formation, complement activation, and secondary renal processing of degradation products and dissociated labels. We then discuss how parental cell identity shapes intrinsic membrane signatures, such as CD47, CD55, and integrins, which can influence immune recognition, biodistribution, and baseline residence time. Building on this source biology, we evaluate engineering strategies that enhance systemic persistence and functional delivery, including stealth coatings (e.g., PEGylation) for prolonging systemic circulation, membrane fusion or biomimetic cloaking for surface functionalization, and hydrogel depots for localized sustained release. Finally, we highlight emerging paradigms, including stimuli‐responsive and microenvironment‐adaptive designs, and discuss translational considerations such as manufacturability, quality control, safety, and reproducible pharmacokinetic readouts. By linking sEV source‐dependent biology to tunable surface and formulation engineering, this review proposes evidence‐informed design considerations for developing long‐circulating sEV carriers across cancer therapy, tissue repair, and immunomodulation.
Zitieren
APA
Jia, W., Wang, D., Zhang, L., Xuan, R., Li, B., & Xu, R. (2026). Prolonging sEV Circulation for Drug Delivery: Integrating Cellular Origin With Surface Bioengineering. WIREs Nanomedicine and Nanobiotechnology, 18(6). https://doi.org/10.1002/wnan.70093
Vancouver
Jia W, Wang D, Zhang L, Xuan R, Li B, Xu R. Prolonging sEV Circulation for Drug Delivery: Integrating Cellular Origin With Surface Bioengineering. WIREs Nanomedicine and Nanobiotechnology. 2026;18(6). doi:10.1002/wnan.70093
BibTeX
@article{Jia2026,
author = {Jia, Wen‐Hao and Wang, Dan and Zhang, Le‐Tian and Xuan, Ru‐Chen and Li, Bo‐Wen and Xu, Rui},
title = {Prolonging sEV Circulation for Drug Delivery: Integrating Cellular Origin With Surface Bioengineering},
journal = {WIREs Nanomedicine and Nanobiotechnology},
year = {2026},
volume = {18},
number = {6},
doi = {10.1002/wnan.70093}
}
EUVIMED